Ro launches Wegovy pill through deal with Novo Nordisk
Ro first integrated directly with Novo Nordisk in April 2025 and has been a key part of the manufacturer's direct-to-patient expansion to date.
Ro first integrated directly with Novo Nordisk in April 2025 and has been a key part of the manufacturer's direct-to-patient expansion to date.
Camber’s year featured broad generic launches, specialty and oncology introductions, emphasizing access, affordability, and supply reliability in the U.S.
Customers can support public school districts’ food programs through March 31.
U.S. drops childhood vaccine recommendations for flu, rotavirus, meningococcal and hepatitis A.
A new feature in the Libre app helps people with diabetes make informed, real-time food choices before eating.
Wearable technology offering real-time metabolic feedback, including watches, rings and continuous glucose monitors, are the most revolutionary health technology of the future.
Consumers can soon go to GoodRx for Weight Loss to determine eligibility and obtain a prescription for the first and only oral GLP-1 formulation.
Wegovy pill now broadly available through over 70,000 US pharmacies such as CVS and Costco.
FY26 funding amounts released as NACDS urges states to implement pharmacy-centered solutions.
CMS made funding awards to all 50 states.
Companion provides insights on partnerships for improving medication use quality.
The approval expands the Wegovy portfolio beyond injections, providing a new administration option for patients.
This initiative aligns with PTCB's commitment to the advancement of the entire pharmacy technician field.
Activity is ramping up across most U.S. regions, with spikes in the Northeast and the Mountain West, as the new subclade K variant emerges and may affect population immunity.
The agreements reduce prices on drugs that treat numerous costly and chronic conditions.
The company has committed more than $70 billion in U.S. investments to boost domestic production and innovation.